The trial realized each its Major endpoints, with semaglutide 2.four mg demonstrating statistically important and exceptional advancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH as compared to placebo.1Semaglutide comes in a